If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.875
Bid: 9.50
Ask: 10.25
Change: 0.00 (0.00%)
Spread: 0.75 (7.895%)
Open: 9.875
High: 9.875
Low: 9.875
Prev. Close: 9.875
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

Mon, 05th Feb 2024 14:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ECR Minerals PLC - Australia-focused gold exploration company - Drills seven successful holes, and says there is evidence of anomalous gold with the best result being 23.39 grammes per tonne of gold over metre. Says the best sample still has 4.7 g/t of gold in the tailings of the initial results. Chief Executive Officer Mike Whitlow says: "This is an encouraging start to our examination of Davey Road. Based on ECR's work historically in this region, our expectation was that any gold would be both course and confined within narrow veins. These preliminary results support this assumption and consequently analysis of the bulk samples is a necessary step before we have a full picture of the geology. There is plenty so far to be pleased with but these results are indicative only and we look forward to gaining a better understanding of the location once full testing is complete."

----------

FireAngel Safety Technology Group PLC - Coventry, England-based developer and supplier of home safety products - Expects to report sales for 2023 of approximately GBP41.0 million, down 29% from GBP57.5 million a year ago. Says UK Trade division performance suffered from the restructuring in its sales team. International sales also remained comparatively depressed in the second half of 2023, it says, as new legislation in Benelux in 2022, which had led to a surge in customer demand in the region for products during 2022, was not carried into 2023 as customers looked to reduce inventory intake.At December 31, FireAngel had net debt of GBP3.1 million, down from GBP4.8 million in 2022.

----------

Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - Expands its NoPhish email security tool to Google Mail users. Says NoPhish employs advanced analysis algorithms to evaluate the content and legitimacy of the reported emails, offering instant feedback to the user. In cases where an email is identified as suspicious or malicious, NoPhish takes proactive measures by automatically removing the email from the user's inbox, thereby mitigating the risk of accidental exposure to harmful content. CEO Raluca Saceanu says: "We are delighted to bring NoPhish to Google Mail users. Our mission has always been to provide cutting-edge, user-friendly cybersecurity tools and by making NoPhish available on one of the world's most widely used email platforms, we are taking a significant step towards making the digital world safer for everyone. The integration signifies major advancement in email security, as Google Mail's extensive user base can now benefit from Smarttech247's phishing detection and response technology. This expansion is part of our ongoing efforts to adapt and evolve in the face of ever-changing cyber threats, ensuring users across various platforms can enjoy a safer email experience."

----------

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases - Says Sally Adams resigns as chief development officer, while Callum Scott is named as the new head of development, effective immediately. Says Adams will remain with the company part time for six months to ensure a "smooth and effective transition of responsibilities."

According to Scancell, Scott has more than 15 years of experience in vaccine research and development. Previously, he held the role of technical transfer & formulation development manager at biotech firm Allergy Therapeutics PLC. CEO Lindy Durrant says: "Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future. "I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Appoints Camillo Pane as chair, effective February 19. He will be replacing Jo LeCouilliard. "Jo and the board feel that it is now appropriate for her to step down from the board and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation," says Alliance Pharma. Senior Independent Director Richard Jones says: "On behalf of the Alliance board and the company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future. We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy. In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more
16 Dec 2019 13:30

Scancell inks AvidiMab agreement with Chinese biotech company

(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.

Read more
16 Dec 2019 09:21

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Read more
12 Dec 2019 14:23

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.